Table 2 Frequency of injection in the year following incident treatment of aflibercept and ranibizumab
Number of injections | 1 | 2 | 3 | 4 | 5–6 | 7–9 | ≥ 10 | Mean (median | p |
|---|---|---|---|---|---|---|---|---|---|
Months 1–12 after incident treatment | |||||||||
Total (N = 3′058) | 250 (8.2) | 235 (7.7) | 558 (18.2) | 312 (10.2) | 582 (19.0) | 688 (22.5) | 433 (14.2) | 5.8 (5) | |
Aflibercept (N = 790) | 52 (6.6) | 39 (4.9) | 141 (17.8) | 67 (8.5) | 151 (19.1) | 227 (28.7) | 113 (14.3) | 6.2 (6) | |
Ranibizumab (N = 2′268) | 198 (8.7) | 196 (8.6) | 417 (18.4) | 245 (10.8) | 431 (19.0) | 461 (20.3) | 320 (14.1) | 5.7 (5) | < 0.001 |
Months 4–12 after incident treatment | |||||||||
Aflibercept (N = 589) | 73 (12.4) | 79 (13.4) | 94 (16.0) | 95 (16.1) | 138 (23.4) | 82 (13.9) | 28 (4.8) | 4.4 (4) | |
Ranibizumab (N = 1′499) | 260 (17.3 | 212 (14.1 | 248 (16.5) | 173 (11.5) | 318 (21.2) | 209 (13.9) | 79 (5.3) | 4.3 (4) | |
Total (N = 2′088) | 333 (15.9) | 291 (13.9) | 342 (16.4) | 268 (12.8) | 456 (21.8) | 291 (13.9) | 107 (5.1) | 4.3 (4) | 0.066 |